Therapeutic efficacy and safety of oral tranexamic acid 250 mg once a day versus 500 mg twice a day: a comparative study

被引:0
作者
Bhumika Chowdhary
Vikram K. Mahajan
Karaninder S. Mehta
Pushpinder S. Chauhan
Vikas Sharma
Anuj Sharma
Sanket Vashist
Prabal Kumar
机构
[1] Department of Dermatology,
[2] Venereology and Leprosy,undefined
[3] Dr. R. P. Govt. Medical College,undefined
来源
Archives of Dermatological Research | 2021年 / 313卷
关键词
MASI score; Melasma treatment; Oligomenorrhea; Pigmentary disorders; Tranexamic acid;
D O I
暂无
中图分类号
学科分类号
摘要
Oral tranexamic acid (TXA) 250 mg twice daily has been used effectively for 4 weeks to 6 months to treat melasma. As relapses are frequent on discontinuation, a minimum effective dose of TXA that can be used safely for long time remains unknown. We compared the efficacy of oral TXA 250 mg once daily and 500 mg twice daily given for 16 weeks in 132 (m:f 23:109) adults with melasma. 42 patients in Group-A (TXA 250 mg/d) and 46 patients in Group-B (TXA 500 mg twice/d) completed the study. They were followed up at 4-week interval for percentage reduction in baseline Melasma Area Severity Index (MASI) and at 24 and 28 weeks for relapse. Therapeutic response, for both as per-protocol and intention-to-treat analysis, was scored as very good (> 75% reduction), good (51–75% reduction), moderate (25–50% reduction), mild (< 25% reduction) or no improvement. Reduction in mean MASI score at 4 weeks was not statistically significant in Group-A but it decreased significantly 8 weeks onwards and was comparable with that in Group-B. The relapse rate was higher in Group-B (10.8%) than Group-A (4.7%) at the end of 28 weeks. Oligomenorrhoea and abdominal discomfort in few patients did not necessitate treatment discontinuation. TXA 500 mg twice daily showed early reduction in mean MASI score compared to 250 mg given once daily with comparable safety and therapeutic efficacy at 16 weeks. Open-label cross-sectional design, no control arm, small number of patients in each group, MASI score being subjective assessment tool, short duration of treatment and follow-up are study limitations.
引用
收藏
页码:109 / 117
页数:8
相关论文
共 128 条
[1]  
Achar A(2011)Melasma: a clinico-epidemiological study of 312 cases Indian J DermatoL 56 380-382
[2]  
Rathi SK(2012)Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial J Cosmet Laser Ther 14 150-154
[3]  
Kanechorn Na Ayuthaya P(2013)Microinjections and microneedling in patients with melasma J Cutan Aesthet Surg 6 139-143
[4]  
Niumphradit N(2009)Melasma in Latin America: options for therapy and treatment algorithm J Eur Acad Dermatol Venerol 23 760-772
[5]  
Manosroi A(2013)Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser J Dermatol Treat 24 292-296
[6]  
Nakakes A(2016)Tranexamic acid: An emerging depigmenting agent Pigment Int 3 66-71
[7]  
Budamakuntla L(2010)Aggravating factors for melasma: a prospective study in 197 Tunisian patients J Eur Acad Dermatol Venereol 24 1060-1069
[8]  
Loganathan E(2012)Oral tranexamic acid for the treatment of melasma Kathmandu Univ Med J 10 40-43
[9]  
Suresh DH(2019)A randomized, open-label, comparative study of oral tranexamic acid and tranexamic acid microinjections in patients with melasma Indian J Dermatol Venereol Leprol 85 39-43
[10]  
Shanmugam S(2007)The vascular characteristics of melasma J Dermatol Sci 46 111-116